Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 InNexus Biotechnology Develops New EGFR Antibody | Contract Pharma

What are you searching for?

Sign in
Breaking News

InNexus Biotechnology Develops New EGFR Antibody

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

InNexus Biotechnology has developed a new antibody product from its DXL platform technology, DXL1218 (EGFR), for the potential treatment of colorectal cancer.
   
“Recent experimental data suggests that DXL1218 (EGFR) is superior to competing commercialized products on the market, such as Erbitux, in terms of potency and efficacy,” said Jeff Morhet, chief executive officer and chairman of InNexus. “I am very excited, as this latest development lends further support to the robustness and predictability of the DXL platform and the superiority of products from the platform over presently commercialized offerings.”
   
Research partner, Pablo Legorreta, chief executive officer of Royalty Pharma, said, “We are quite pleased with the rapid progress of InNexus. Jeff has had a vision for rapid product development based on DXL technology coupled with advanced in vivo studies and a significant regulatory strategy. We look forward to their continued rollout of products and performance.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters